Sharif Kullab

459 total citations
11 papers, 143 citations indexed

About

Sharif Kullab is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sharif Kullab has authored 11 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sharif Kullab's work include HER2/EGFR in Cancer Research (4 papers), Cancer Genomics and Diagnostics (3 papers) and Advanced Breast Cancer Therapies (2 papers). Sharif Kullab is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer Genomics and Diagnostics (3 papers) and Advanced Breast Cancer Therapies (2 papers). Sharif Kullab collaborates with scholars based in Saudi Arabia, France and Tunisia. Sharif Kullab's co-authors include Jean‐Marc Nabholtz, Xavier Durando, Frédérique Penault‐Llorca, P. Chollet, Catherine Abrial, Nina Radosevic‐Robin, Nasséra Chalabi, Marie‐Ange Mouret‐Reynier, Fabrice Kwiatkowski and Isabelle Van Praagh and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

Sharif Kullab

11 papers receiving 142 citations

Peers

Countries citing papers authored by Sharif Kullab

Since Specialization

Citations

This map shows the geographic impact of Sharif Kullab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharif Kullab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharif Kullab more than expected).

Fields of papers citing papers by Sharif Kullab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharif Kullab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharif Kullab. The network helps show where Sharif Kullab may publish in the future.

Co-authorship network of co-authors of Sharif Kullab

This figure shows the co-authorship network connecting the top 25 collaborators of Sharif Kullab. A scholar is included among the top collaborators of Sharif Kullab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharif Kullab. Sharif Kullab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Title	Journal	Authors	Indexed citations
1	BRCA testing and management of BRCA-mutated early-stage breast cancer: a comprehensive statement by expert group from GCC region	Frontiers in Oncology	Humaid O. Al‐Shamsi, Syed Hammad Tirmazy et al.	2
2	Disseminated Nocardiosis in a Breast Cancer Patient Caused by Nocardia otitidiscaviarum: A Case Report of Tertiary Centre in Saudi Arabia	Cureus	Sharif Kullab, E. Nohuz et al.	2
3	Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant.	Journal of Clinical Oncology	Khalid Alsaleh, Hikmat Abdel‐Razeq et al.	2
4	Breast-cancer detection using blood-based infrared molecular fingerprints	BMC Cancer	Kosmas V. Kepesidis, Marinus Huber et al.	13
5	Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia.	Journal of Clinical Oncology	Sharif Kullab et al.	1
6	A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)	Annals of Oncology	Omalkhair Abulkhair, Meteb Al‐Foheidi et al.	1
7	Prognostic value of circulating cytokines in breast cancer: A prospective study in sixty breast cancer patients in Tunisia.	Journal of Clinical Oncology	Sharif Kullab et al.	1
8	Vaginal Lymphoma: A Possible Cause of Genital Hemorrhage	Turkish Journal of Hematology	E. Nohuz, Sharif Kullab et al.	2
9	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?	Critical Reviews in Oncology/Hematology	Nasséra Chalabi, Catherine Abrial et al.	68
10	Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience	Chemotherapy	Romain Rivoirard, Cyrus Chargari et al.	5
11	Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer	International Journal of Cancer	Jean‐Marc Nabholtz, Nasséra Chalabi et al.	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact